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Abstract
Background: ANCA-Associated Systemic Vasculitis (AASV) is characterized by leukocytoclasis, accumulation of unscavenged
apoptotic and necrotic neutrophils in perivascular tissues. Dysregulation of neutrophil cell death may contribute directly to
the pathogenesis of AASV.
Methods: Neutrophils from Healthy Blood Donors (HBD), patients with AASV most in complete remission, Polycythemia
Vera (PV), Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA) and renal transplant recipients (TP) were
incubated in vitro, and the rate of spontaneous apoptosis was measured by FACS. Plasma levels of cytokines and sFAS were
measured with cytometric bead array and ELISA. Expression of pro/anti-apoptotic factors, transcription factors C/EBP-a,C /
EBP-b and PU.1 and inhibitors of survival/JAK2-pathway were measured by real-time-PCR.
Results: AASV, PV and RA neutrophils had a significantly lower rate of apoptosis compared to HBD neutrophils (AASV
50614% vs. HBD 64611%, p,0.0001). In RA but not in AASV and PV, low apoptosis rate correlated with increased plasma
levels of GM-CSF and high mRNA levels of anti-apoptotic factors Bcl-2A1 and Mcl-1. AASV patients had normal levels of G-
CSF, GM-CSF and IL-3. Both C/EBP-a, C/EBP-b were significantly higher in neutrophils from AASV patients than HBD. Levels
of sFAS were significantly higher in AASV compared to HBD.
Conclusion: Neutrophil apoptosis rates in vitro are decreased in AASV, RA and PV but mechanisms seem to differ. Increased
mRNA levels of granulopoiesis-associated transcription factors and increased levels of sFAS in plasma were observed in
AASV. Additional studies are required to define the mechanisms behind the decreased apoptosis rates, and possible
connections with accumulation of dying neutrophils in regions of vascular lesions in AASV patients.
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Introduction
AASV is characterized by leukocytoclasis, infiltration and
accumulation of unscavenged apoptotic or necrotic neutrophils
in perivascular tissues and fibrinoid necrosis of the vessel walls
[1][2]. Activated, apoptotic and necrotic neutrophils are seen in
histological samples from patients with Granulomatosis with
polyangiitis (GPA) with respiratory disease [3]. Histological
evidence suggests that neutrophil apoptosis may play a central
role in the pathogenesis of AASV and production of ANCA (Anti-
Neutrophil Cytoplasmic Antibodies) [4][5]. Injection of brown
Norway rats with syngenic apoptotic neutrophils was shown to
induce ANCA but not AASV, suggesting that additional factors
are required for disease pathogenesis [6].
Higher levels of plasma PR3 have been reported in patients with
quiescent AASV (in remission) compared to Healthy Blood
Donors (HBD) [7][8]. Furthermore, membrane PR3-positive
(mPR3
+) neutrophils are more abundant in individuals with
quiescent AASV indicating that PR3 plays an active role in the
pathogenesis of AASV and not just a marker of inflammation. It
has been shown that PR3 can trigger cultured endothelial cell
apoptosis; however, the mechanism was not defined [9]. PR3
activates procaspase-3 into a specific 22-kDa fragment, localized to
the plasma membrane-enriched compartment and segregated
from its target cytosolic proteins that promote apoptosis, thus
causing activation but not apoptosis [10]. Vong et al showed that
recombinant PR3 or the membrane fraction of cells stably-
transfected with PR3 can cleave Annexin-A1 (AnxA1), suggesting
that AnxA1 may be a physiologically relevant substrate for PR3
[11]; AnxA1 was recently recognized as an important inducer or
promotor of neutrophil apoptosis. Harper et al reported faster
apoptosis in neutrophils from patients with active vasculitis
compared to neutrophils from patients with quiescent vasculitis
or from HBD; neutrophils from patients with active vasculitis also
had higher levels of mPR3 and superoxide production [12].
PR3 can be mobilized to the plasma membrane in the absence
of prior neutrophil priming and independent of degranulation
during the apoptotic process [13]. Kantari et al showed that
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promotes its translocation to the plasma membrane in a flip-flop
manner during apoptosis [14]. However, the level of mPR3 is
similar in apoptotic and non-apoptotic primed neutrophils,
implying that the mPR3 on apoptotic neutrophils may be a result
of minor trauma during neutrophil isolation [15]. Our group has
previously shown that the level of mPR3 on aging neutrophils is
slowly decreasing and is not a pre-apoptotic marker [16]. Thus,
PR3 seems to be linked to neutrophil apoptosis, though the exact
nature of this relationship is not clear. As there is definite evidence
for increase PR3 and neutrophil accumulation in AASV, it is likely
that neutrophil apoptosis may contribute to disease pathogenesis.
Accumulation of neutrophils in AASV tissues may occur as a
result of either an increase in granulopoiesis, defective apoptosis or
impaired clearance of apoptotic neutrophils. Based on elevation of
PR3 in quiescent AASV and its link to neutrophil apoptosis, we
hypothesized that the neutrophil apoptosis in AASV is dysregu-
lated even during remission. In this study, we focus on early events
explaining the origin of ANCA by studying patients in remission;
our attempt was to confirm abnormality in apoptotic rate in AASV
and to elucidate the mechanisms underlying the hypothesized
dysregulation. The rates of spontaneous in vitro apoptosis were
noted in neutrophils from AASV patients most in complete
remission or with mild activity and other study populations; these
were analyzed in relation to clinical data. The expression of
selected genes and proteins involved in neutrophil survival was
evaluated in relation to apoptosis.
Methods
Patients
During the period between September 2006 and February
2008, 44 AASV patients (most in complete remission or having
mild activity) from the Department of Nephrology, Lund
University Hospital were recruited into the current study. Patients
diagnosed with AASV were classified as GPA or Microscopic
Polyangiitis (MPA) using the European Medicines Agency (EMEA)
algorithm [17]. The vasculitis activity status of all patients was
determined using the Birmingham Vasculitis Activity Score
(BVAS) [18]. AASV patients were receiving the following
treatments at time of sampling: 21 patients- cytotoxic drugs and
steroids; 10 patients- cytotoxic drugs; 5 patients- steroids; 8
patients- no treatment (Table 1). None of the patients had received
biological treatment.
Additional study participants included HBD from the local
blood bank, TP recipients from the Department of Nephrology,
PV patients from the Department of Haematology, SLE and RA
patients from the Department of Rheumatology, all at Lund
University Hospital (Table 1). None of the disease controls was
treated with biological treatment.
This study was approved by the Regional Ethical Review Board
and performed in accordance with the Declaration of Helsinki.
Informed signed consent was obtained from all study participants.
Blood sampling and separation
Leukocytes were isolated by centrifugation on Polymorphprep
(Axis- Shield, Oslo, Norway). Plasma band was used to measure
levels of different cytokines. The neutrophil band was used to study
neutrophil survival, apoptosis and necrosis by FACS and to extract
RNA for real time PCR.
Neutrophil in vitro culture and FACS
Isolated neutrophils were cultured in AIM-V medium (neither
calf nor human serum was used) and incubated in an incubator with
5% CO2 in humid atmosphere, at 37uC, for 20 h. An aliquot (10
6
neutrophils)wastaken and incubatedfor5 mininthe darkwith1 ml
Annexin-V(markerofapoptosis fromInvitrogen,Molecularprobes,
Oregon, USA) and 10 ml 7-AAD (marker of necrosis from BD-
Biosciences, San Jose, CA, USA). Annexin-V was conjugated with
Alexa 488 while 7-AAD was conjugated with PE (Phycoerythrin).
Neutrophils were then analyzed by flow cytometry using BD
FACSCanto II (BD Pharmingen, CA, USA) to report % of
apoptotic, necrotic or alive cells after 20 h of in vitro culture.
RNA extraction
Total RNA was extracted with RNeasy Mini kit (Qiagen, VWR
International, West Chester, PA, USA) according to the
Table 1. Demographic data for the AASV patients and controls.
Variable GPA MPA HBD PV TP SLE RA
N 3 1 1 3 9 31 72 0 2 1 2 1
Age years; 61 64 41 61 51 44 63
median (range) (18–86) (37–87) (21–68) (37–81) (29–71) (22–68) (32–86)
F/M ratio 15/16 7/6 36/57 7/10 7/13 20/1 13/8
PR3-ANCA 26 1 - - - - -
MPO-ANCA 3 12 - - - - -
ANCA negative 2 0 - - - - -
BVAS 0–1 23 8 - - - - -
BVAS 2–5 6 5 - - - - -
BVAS.5 2 0 --- - -
DAS; median (IQR) - - - - - - 3.96 (3.1–4.5)
SLEDAI; median (IQR) - - - - - 4 (0–8) -
Prednisolone dose mg/day; median (IQR) 1.25 (0–5) 5 (0–7.5) - - 5 (5–7.5) 7 (5–10) 2.5 (0–5)
AASV=ANCA-associated Systemic Vasculitis. GPA=Granulomatosis with polyangiitis. MPA=Microscopic polyangiitis. N=Number of subjects. F=Female. M=Male.
HBD=healthy blood donors. PV=Polycythemia Vera. TP=renal transplant recipients. SLE=Systemic Lupus Erythematosus. RA=Rheumatoid Arthritis.
BVAS=Birmingham Vasculitis Activity Score. DAS=Disease activity score. SLEDAI=SLE disease activity index. IQR=Interquartile range.
doi:10.1371/journal.pone.0032439.t001
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photometric analysis using NanoDrop (Saveen& Werner, Malmo ¨,
Sweden).
Quantitative PCR assay
cDNA was prepared from total RNA using TaqMan Reverse
Transcription Kit (Applied Biosystems, Foster City, CA, USA)
according to the manufacturer’s instructions. Briefly, reverse
transcription was performed using random hexamers, MultiScribe
reverse transcriptase, RNase inhibitor, dNTPs, 5.5 mM MgCl2,
reverse transcription buffer, and 200 ng total RNA in a volume of
50 ml. The reaction cycle was 25u/10 min, 48u/30 min and 95u/
5 min. Quantitative PCR assays were performed in an ABI
PRISM 7000 Sequence Detector (Applied Biosystems, CA, USA)
with TaqMan Universal Master Mix UNG under standard
conditions. Assay on Demand provided a unique combination of
forward and reverse primers and fluorescent MGB-probes for each
target gene (Bax, Mcl-1, Bcl-2A1, c-IAP2, C/EBP-a, C/EBP-b,
PU.1, SHIP-1, SOCS1 and SOCS3). Cyclophilin A expression
was used as an internal control for data normalization. Each 25 ml
reaction contained the amount of cDNA produced from 10 ng
RNA. All reactions were performed in triplicates. Q-PCR data
were analyzed using the DDCt method with normalization to
Cyclophilin A and standard 2
(2DD Ct) calculations [19].
Measurement of neutrophil growth factors and soluble
FAS in plasma by ELISA and cytometric bead array (CBA)
G-CSF, GM-CSF, IL-3 and soluble Fas (sFAS) were measured
in plasma with the QuantikineH ELISA Kit (R&D systems,
Abingdon, UK), which was used according to the manufacturer’s
protocol.
G-CSF, GM-CSF, IL-3, TNF-a, IFN-c, IL-1b, IL-2, Il-4, IL-6
and IL-8 were simultaneously analyzed in 50 ml plasma by flow
cytometry using the BD CBA Human Soluble Protein Flex Set
system (BD Pharmingen, CA, USA) according to the manufactures
instructions.
Statistical analysis
For continuous variables, an unpaired t-test was used to
measure statistical significance of differences between two groups.
Results are presented as mean6 SD. For data sets that follow a
non-Gaussian distribution, statistical significance was measured
using a Mann-Whitney test. Results are presented as median and
range or interquartile range (IQR).
One-way ANOVA with Bonferroni’s post-test was used to
compare data from more than two groups. Correlations were
analyzed using Pearson rank test. Spearman rank test was used for
non-parametric data. A two-sided p,0.05 was considered to be
statistically significant.
Results
Neutrophil apoptosis in vitro
Apoptosis, necrosis and survival of neutrophils from 44 patients
with AASV, 93 HBD, 20 TP recipients, 17 PV, 21 SLE and 21
RA patients was quantified after 20 h in culture as described in the
method section. The results showed a significantly higher rate of
survival (mean 6SD 34613% Vs 236 9%, p,0.0001; Figure 1a)
and lower rate of apoptosis (50614% Vs 64611%, p,0.0001;
Figure 1b) in AASV neutrophils compared to neutrophils from
HBD. Similar results were obtained when examining neutrophils
from RA and PV patients, with survival rates of 31613% and
49615% (p=0.015 and p,0.0001), and apoptosis rates of
57612% and 41614% (p=0.027 and p,0.0001). For necrosis
there was no significant difference between neutrophils from
AASV, PV and RA neutrophils compared to HBD neutrophils
(data not shown).
No correlation between neutrophil apoptosis and clinical
data
To ascertain that the reduced rate of apoptosis was not a
consequence of gender, age, renal function, general inflammation
or treatment, apoptosis rates were correlated with clinical data for
the AASV patients. No significant correlations were found with
gender (men and women had similar rates: 49611% vs. 51615%;
p=0.5, n=22 for men and n=22 for women) or age (Spearman
r=0.01, p=0.9, n=44). There was no correlation with serum
Creatinine concentration (Spearman r=20.13, p=0.4, n=44) or
estimated GFR (Spearman r=0.1, p=0.5, n=44). Similar results
were observed for patients with GPA and MPA (49612% Vs
53616%; p=0.4; n=31 for GPA and n=13 for MPA). There
was no correlation with CRP (Spearman r=20.11, p=0.5,
n=44). Regarding disease activity, no conclusion could be drawn;
since patients in remission (BVAS,2, n=31) had comparable
apoptosis rates as patients with moderate vasculitis activity (BVAS
2–5, n=11). Patients with high vasculitic activity (BVAS.5, n=2)
had tendency towards lower apoptosis rate (51614% and 5269%
Vs 28613%; p=0.09); this difference was not significant, though
the number of patients was too small to draw a definite conclusion.
Figure 1. Rate of neutrophil survival and apoptosis. Neutrophils
isolated from 60 HBD, 44 AASV patients, 8 PV patients, 18 TP, 21 SLE
patients, and 20 RA patients were cultured in vitro in AIM-V medium.
The percentage of surviving neutrophils (1a) and apoptotic neutrophils
(1b) was measured after 20 hours. % Neutrophil survival=% of annexin-
V negative and 7-AAD negative cells after 20 hour culture. % Neutrophil
apoptosis=% of annexin-V positive and 7-AAD negative cells after
2o hour culture. HBD=healthy blood donors. AASV=ANCA-Associated
Systemic Vasculitis. PV=Polycythemia Vera. TP=renal transplant
recipients. SLE=Systemic Lupus Erythematosus. RA=Rheumatoid
Arthritis.
doi:10.1371/journal.pone.0032439.g001
Neutrophil Apoptosis in Vasculitis
PLoS ONE | www.plosone.org 3 March 2012 | Volume 7 | Issue 3 | e32439We could not demonstrate any influence ongoing steroid
treatment on the measured rate of apoptosis, as there was no
correlation between neutrophil apoptosis and the dose of
prednisolone mg/day (Spearman r=20.11, p=0.5). We divided
the patients into two subgroups; a subgroup treated with steroids
and a subgroup without steroids: there was no difference between
the two subgroups in regard to neutrophil apoptosis (49613% Vs
51615%, P=0.6). For anti-proliferative drugs the situation was
somewhat more complex; the 27 AASV patients who were on
treatment tended to have lower apoptosis rates as compared to the
8 patients who were off all kinds immunosuppressive treatment
(47612% Vs 57615%; p=0.02), with no obvious difference
between drugs. The 10 methotrexate treated patients had a mean
rate of 46611%, compared with 48612% for 10 patients on
azathioprine and 48613% for 7 patients on mycophenolate
mofetil (p=0.94). In contrast, 11 renal transplant recipients on
mycophenolate mofetil had a mean apoptosis rate of 57616%.
Plasma factors potentially influencing neutrophil survival
in AASV
The plasma levels of G-CSF, GM-CSF, IL-3, TNF-a, IFN-c,
IL-1b, IL-2, IL-4, IL-6 and IL-8 were measured using Cytometric
Bead Analysis (CBA), and G-CSF, GM-CSF, IL-3 and sFAS were
also quantified using ELISA. For most cytokines examined, there
were no significant difference between HBD and AASV. IL-3 was
below the detection limit in all tested samples. G-CSF was elevated
in plasma samples from 10/44 AASV patients (median, range:
31.7, 20–72 pg/ml) and 4/21 RA patients (26.9, 17–43 pg/ml-
Table 2), but there was no correlation between the plasma levels of
G-CSF and the rates of neutrophil survival and apoptosis in these
patients. Patients were divided into two subgroups according to
their G-CSF levels; there was no difference between the two
subgroups in their neutrophil survival/apoptosis (Table 2). G-CSF
was also detected in 10/93 HBD (28.3, 15–46 pg/ml), which is
slightly lower than AASV, but the difference was not significant
(P=0.29).
IFN-c levels were undetectable in plasma of HBD, while 5
AASV patients had elevated levels of IFN-c in their plasma
(median 19 pg/ml, range 8–25 pg/ml).
GM-CSF was ,2 pg/ml in the majority of samples, which is
within the expected normal range for healthy individuals. GM-
CSF was elevated in plasma samples from 4/44 AASV patients
(median, range: 484.2, 7.7–3072 pg/ml) and 8/21 RA patients
(median, range: 37, 11–178 pg/ml), Table 3. Overall there was no
significant correlation between the plasma levels of GM-CSF and
the rates of neutrophil survival, apoptosis or necrosis. The 4 out of
44 AASV patients with high GM-CSF showed only marginally
higher survival rates and the difference was not statistically
significant (38614% Vs 34613%, p=0.5). However the 8 RA
patients with elevated GM-CSF levels exhibited a significantly
reduced apoptosis rate (5169% Vs 61612% apoptosis rate,
p=0.034) combined with a tendency for increased survival
(37610% Vs 27614%, p=0.09), Table 3.
The levels of sFAS were significantly higher in the plasma of
AASV patients compared to healthy controls (mean6SD 0.860.3
Vs 0.460.1 pg/ml, P,0.0001), but there was no correlation
between levels and rate of spontaneous apoptosis (Pearson
r=0.01, P=0.9).
Apoptosis and proportion of PR3
+/CD177
+ neutrophils
In accordance with previous studies we found an increased
fraction of neutrophils double positive for membrane PR3
Table 2. Neutrophil survival among patients with high G-CSF levels.
Patients G-CSF pg/ml Neutrophil survival %
AASV 1 20.37 33%
AASV 2 22.68 51%
AASV 3 23.69 20%
AASV 4* 27.16 52%
AASV 5 30.76 35%
AASV 6 32.67 40%
AASV 7 33.1 30%
AASV 8 41.5 34%
AASV 9 68.19 34%
AASV 10 72.32 39%
Median of the 10 AASV patients above (range) 31.7 (20–72) 35% (20%–52%)
Median of the 34 remaining AASV patients (range) UD 33% (8%–68%)
RA 1 17.05 57%
RA 2 22.45 10%
RA 3** 26.98 42%
RA 4 34.55 30%
RA 5*** 42.87 31%
Median of the 5 RA patients above (range) 26.9 (17–43) 31% (10%–57%)
Median of the 15 remaining RA patients (range) UD 30% (12%–48%)
% Neutrophil survival=% of annexin-V negative and 7-AAD negative cells after 20 hour culture. AASV=ANCA-associated Systemic Vasculitis. RA=Rheumatoid Arthritis.
GM-CSF=Granulocyte-Colony Stimulating Factor. UD=Undetectable (,2 pg/ml).
*/**/***Are signals for the common patients between table 2 and 3.
doi:10.1371/journal.pone.0032439.t002
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for AASV, 58621% for HBD; p=0.004, n=52 for AASV and
n=91 for HBD). There was, however, no correlation between the
percentage of double-positive neutrophils and the rate of apoptosis
in all the groups of all subjects participated in the study (Pearson
r=20.02, p=0.7, n=156).
mRNA expression analysis
The mRNA expression of the following genes was analyzed:
anti–apoptotic factors (c-IAP2, Bcl2-A1 and Mcl-1), pro-apoptotic
factor (Bax), transcription factors (C/EBP-a, C/EBP-b and PU.1),
growth factor receptors (G-CSFR, GM-CSFR alpha, GM-CSFR
beta) and suppressors of cytokine signaling (SHIP-1, SOCS1,
SOCS3). Quantitative PCR as performed for their respective
mRNA transcripts. These were quantified in neutrophils from
patients with AASV, HBD, PV, RA and TP.
The results showed slightly higher expression of Bcl-2A1 (Median,
range: 1.02, 0.1–7.3 Vs0.58, 0.09–4.7, p=0.25), Mcl-1 (1.16, 0.1–8.0
Vs 0.57, 0.05–3.7, p=0.13) and Bax (1.23, 0.07–5.5 Vs 0.68, 0.08–
3.9, p=0.14) in AASV neutrophils than in HBD neutrophils;
however, these differences were not statistically significant (Table 4).
No significant correlation was observed between the rates of
neutrophil apoptosis or necrosis in neutrophils from AASV patients
and relative expression of pro-/anti-apoptotic factors. However,
expression of Bcl-2A1 (Median, range: 1.96, 0.05–6.5 Vs 0.58, 0,09–
4.7,p=0.004)andMcl-1(1.49,0.14–7.23,p=0.007)wassignificantly
higher in RA neutrophils than in HBD neutrophils (Table 4).
Expression of pro and anti-apototic factors was not higher in
neutrophilsfromPVpatientsandTPrecipientsthaninHBD(Table4).
Transcription factors involved in the process of granulopoiesis
were quantified in neutrophils from HBD (n=22), AASV (n=25),
RA (n=10), PV (n=10) patients and TP (n=12). Results showed
significantly higher mRNA encoding C/EBP-a and C/EBP-b in
AASV patients than in healthy controls (Table 5). Neutrophils
from PV patients had significantly lower levels of C/EBP-b and
PU.1 than neutrophils from HBD. There was no significant
correlation between mRNA levels of any of the transcription
factors and the rate of neutrophil survival/apoptosis. On the other
hand, there was a significant positive correlation between C/EBP-
a and G-CSF levels in plasma (Spearman r=0.7, p=0.03, n=9)
among AASV patients.
Neutrophils from 31 AASV patients and 23 HBD had similar
mRNA expression of survival/JAK2-pathway inhibitors (SHIP-1,
SOCS1 and SOCS3; p.0.05). mRNA expression of growth factor
receptors was analyzed in 19 AASV patients and 9 HBD; no
significant differences were noted (G-CSFR, GM-CSFR alpha and
beta; p.0.05).
Discussion
Neutrophils release reactive oxygen species and proteases into
the tissue microenvironment, leading to tissue inflammation and
Table 3. Neutrophil survival among patients with high GM-CSF levels.
Patients GM-CSF pg/ml Neutrophil survival %
AASV 1* 7.7 52%
AASV 2 195.71 42%
AASV 3 772.73 41%
AASV 4 3072 18%
Median of the 4 AASV patients above (range) 484 (7.7–3072) 41% (18%–52%)
Median of the 40 remaining AASV patients (range) UD 33% (8%–68%)
RA 1 11.3 38%
RA 2 27.28 47%
RA 3*** 29.15 31%
RA 4 35.41 19%
RA 5 38.48 48%
RA 6 71.89 42%
RA 7** 112.16 42%
RA 8 178.52 30%
Median of the 8 RA patients above (range) 37 (11–178) 40% (19%–48%)
Median of the 12 remaining RA patients (range) UD 24% (10%–57%)
% Neutrophil survival=% of annexin-V negative and 7-AAD negative cells after 20 hour culture. AASV=ANCA-associated Systemic Vasculitis. RA=Rheumatoid Arthritis.
GM-CSF=Granulocyte Macrophage-Colony Stimulating Factor. UD=Undetectable (,2 pg/ml).
*/**/***Are signals for the common patients between table 2 and 3.
doi:10.1371/journal.pone.0032439.t003
Table 4. Gene expression of pro-/anti-apoptotic factors in
neutrophils.
HBD AASV PV TP RA
n1 9 2 0 1 0 1 2 2 1
cIAP2-mRNA 0.93 1.1 1.06 0.77 1.14
Bcl2-A1-mRNA 0.58 1.02 0.55 0.76 1.96*
Bax-mRNA 0.68 1.23 0.49 0.55 0.77
Mcl-1-mRNA 0.57 1.16 0.38 0.68 1.49*
All results are expressed as median fold change relative to Cyclophilin A.
(*)P value,0.05, according to Mann-Whitney test and as compared to HBD.
HBD=healthy blood donors. AASV=ANCA-associated Systemic Vasculitis.
PV=Polycythemia Vera. TP=renal transplant recipients. RA=Rheumatoid
Arthritis.
doi:10.1371/journal.pone.0032439.t004
Neutrophil Apoptosis in Vasculitis
PLoS ONE | www.plosone.org 5 March 2012 | Volume 7 | Issue 3 | e32439injury. When cultured in vitro, in the absence or presence of
insufficient concentrations of neutrophil survival factors, these cells
undergo spontaneous apoptosis [20]. Neutrophils are removed
from tissues via necrosis or apoptosis, followed by phagocytosis by
macrophages [21][22]. Defects in apoptotic pathways could lead
to the persistence of auto-reactive T- or B-cells and development
of autoimmune disease, including AASV [23].
Our study is the first to demonstrate a lower rate of spontaneous
apoptosis and longer in vitro survival in neutrophils from AASV
patients as compared to neutrophils from HBD, SLE patients, and
TP. Decreased apoptosis was also noted in neutrophils from PV
and RA patients, in accordance with previously published data
[24][25]. An accelerated rate of apoptosis and decreased
phagocytosis by macrophages for neutrophils from SLE patients
has been reported previously [26]. Contrary to our results, Harper
et al. showed that neutrophils from AASV patients, especially
those with active disease, have an accelerated rate of apoptosis
[12]. In this study involving 8 patients with active systemic
vasculitis and 17 patients in remission, apoptosis was correlated
with high mPR3 expression and high intracellular superoxide
production. The neutrophils, however, were incubated in DMEM
medium with 10% autologous serum, and in our study we did not
use serum/plasma in the culture of neutrphils in AIM-V medium.
They assessed neutrophil apoptosis after 12 and 18 hours while we
assessed neutrophil apoptosis after 20 hours. Another difference is
in the methods used to assess apoptosis. While we used
simultaneous labeling of neutrophils by annexin-V and 7-AAD
with subsequent measurement by FACS, Harper et al have used
neutrophil morphology and fluorescence microscopy to define
apoptotic neutrophils. In our study we had only two patients with
active disease (BVAS.5), as we chose to study patients in
remission in an attempt to understand early pathophysiological
mechanisms and to exclude inflammation.
Delayed neutrophil apoptosis has been associated with several
diseases and syndromes including sepsis, sleep apnea, cystic
fibrosis, pneumonia, idiopathic pulmonary fibrosis, Behc ¸et disease
in the remission phase of uveitis, inflammatory bowel disease,
systemic inflammatory response syndrome after major trauma and
Kawasaki disease [27][28][29][30]. The occurrence of reduced
apoptosis in such a variety of disorders suggests a common
underlying factor, such as chronic inflammation. However, we did
not observe any correlation between rate of apoptosis and markers
of inflammation or clinical parameters (CRP, BVAS score, GFR).
Moreover, most of our AASV patients were having no or mild
vasculitis activity as revealed by undetectable/low plasma levels of
most of the cytokines tested in our study. Although the use of
immunosuppressive drugs may have confounded the results, the
difference between AASV and TP patients suggests that drugs
could at most account for only a minor part of the prolonged
neutrophil survival.
Increased proportion of CD177
+/PR3
+ subpopulation of
neutrophils is seen in AASV, SLE, as well as in states associated
with increased granulupoiesis such as sepsis. No correlation
between rate of apoptosis and proportion of CD177
+/PR3
+
neutrophils was evident in our data. Growth factor signaling
prolongs survival through production of anti-apoptotic factors
and/or down regulation of pro-apoptotic factors. The expression
of anti-apoptotic Bcl-2A1 is up-regulated by G-CSF, GM-CSF
and LPS, which also promote neutrophil survival [31][32], while
Mcl-1 is up-regulated by GM-CSF, IL-1 and LPS [33]. c-IAP2, an
Inhibitor of Apoptosis Protein (IAP), is selectively up-regulated by
G-CSF, but not by GM-CSF [34]. The pro-apoptotic factor Bax is
down-regulated in response to G-CSF, GM-CSF, IL-3 and IFN-c
[35]. In our study, the mRNA levels of these factors showed no
correlation with reduced apoptosis or necrosis in neutrophils from
AASV or PV patients. However, expression of Bcl-2A1 and Mcl-1
was significantly higher in neutrophils from RA patients than in
HBD, Table 4.
Alteration in neutrophil growth factor signaling may cause
abnormalities in apoptosis. We measured the expression of
transcription factors involved in steady-state and emergency
granulopoiesis [36][37]. The mRNA levels of these factors (C/
EBP-a, C/EBP-b and PU.1) were significantly higher in AASV
patients than in HBD, but were normal in patients with RA or TP
recipients. The target genes of these transcription factors include
many important neutrophil proteins, including G-CSF receptor,
GM-CSF receptor, myeloperoxidase, PR3, elastase, lysozyme and
lactoferrin [38][39]. Thus, elevated expression of these proteins in
AASV neutrophils may enhance their susceptibility/sensitivity to
cytokines. Also, the transcription factors may stimulate neutrophil
survival and granulopoiesis directly, independent of G-CSF and
GM-CSF and their respective receptors [40][41]. Increase of c/
EBP-b indicates ongoing granulopoiesis via the emergency
pathway, which may lead to an increased amount of naı ¨ve
neutrophils in the circulation with possibly an altered phenotype.
Neutrophils from AASV patients had similar mRNA expression of
survival/JAK2-pathway inhibitors and growth factor receptors as
compared to HBD, suggesting that they may not be directly
involved in reduction of apoptosis.
Plasma contains a multitude of neutrophil growth factors.
Previous experiments measuring various cytokines (known to
increase neutrophil survival) failed to show conclusive results.
Christensson et al. showed that AASV patients, in remission, had
higher circulating levels of soluble Fas than HBD and other disease
controls [42]. sFAS is a circulating receptor of death signals in the
plasma; its presence in plasma prevent interaction between FAS
and FASl (Fas ligand), leading to prolonged survival [43]. We
found significantly elevated sFAS levels in patients with AASV,
suggesting a possible role in delaying apoptosis, although the
biological significance of this finding is unclear. Elevated levels of
sFAS could also be related to lymphocyte activation, which is
already reported in AASV even during quiescent disease [44][45].
G-CSF, GM-CSF and IL-3, enhance neutrophil survival and delay
or prevent neutrophil apoptosis [46][47][48]. Plasma levels of IL-3
levels were normal in all vasculitis patient subgroups examined in
this study. GM-CSF levels were higher than normal in 4 (of 44)
AASV patients and in 8 (of 20) RA patients, Table 3. Interestingly,
these 8 RA patients exhibited delayed neutrophil apoptosis as
compared to the other RA patients, indicating different mecha-
Table 5. Gene expression of transcription factors in
neutrophils.
HBD AASV PV TP RA
n2 2 2 5 1 0 1 1 1 0
C/EBP-a-mRNA 0.23 0.83** 0.08* 0.07 0.22
C/EBP-b-mRNA 0.35 3.35*** 0.1** 0.2 0.75
PU-1-mRNA 0.85 1.5 0.3** 0.24 0.35
All results are expressed as median fold change relative to Cyclophilin A.
(*)P value,0.01,
(**)p value,0.001, and
(***)p value,0.0001, according to Mann-Whitney test and as compared to HBD.
HBD=healthy blood donors. AASV=ANCA-associated Systemic Vasculitis.
PV=Polycythemia Vera. TP=renal transplant recipients. RA=Rheumatoid
Arthritis.
doi:10.1371/journal.pone.0032439.t005
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(TNF-a, IFN-c, IL-1b, IL-2, Il-4, IL-6 and IL-8) tested in this
study were undetectable in almost all plasma samples from healthy
controls, and in most of the samples from AASV patients. This
may be secondary to the fact that most of our patients were in
complete remission.
Even though levels of G-CSF, GM-CSF and IL-3, were not
elevated in AASV, they could still cause delayed apoptosis if
AASV neutrophils were to have increased sensitivity to these
cytokines. Our results show no difference between AASV patients
and HBD regarding mRNA expression of G-CSF-Receptor
(CD114) and GM-CSF-receptor (CD116). No previous studies
on CD114 or CD116 expression have been published in regards to
vasculitis patients, although studies on these receptors have been
done in other inflammatory diseases such as inflammatory bowl
disease and showed low/defective CD116 [49]. Future studies
addressing these issues could be very interesting.
In summary, we find decreased spontaneous apoptosis in
AASV, RA and PV, but mechanisms seem to differ. Our data
demonstrating decreased apoptosis, increased mRNA levels of the
C/EBP-a and C/EBP-b transcription factors, together with
previous findings of increased proportion of double positive
CD177
+/PR3
+ cells and increased transcription of the PR3 gene
provides evidence for an altered neutrophil phenotype in AASV. A
higher rate of neutropoiesis/granulopoiesis in AASV together with
a lower rate of neutrophil apoptosis, may contribute to neutrophil
accumulation in regions of inflammation. A definite mechanism
for the delayed apoptosis in AASV could not be defined, our
results are compatible with a role for an unidentified circulating
factor, but intrinsic mechanisms cannot be ruled out. Novel
survival pathways are emerging that have been reviewed recently
by Witko-Sarsat et al [50], describe a cytosolic scaffold protein,
Proliferating Cell Nuclear Antigen (PCNA), a cell cycle regulatory
protein that is usually used by proliferating cells in proliferation, is
used by neutrophils in regulating/inhibiting apoptosis. A recent
study by Witko-Sarsat et al showed increased PCNA expression
(both on mRNA and protein level) in neutrophils from AASV
patients and that may give an explanation for our yet unexplained
finding of prolonged neutruphil survival [51]. However, this
postulate must be tested simultaneously in the same samples/
neutrophils. Improved understanding of mechanisms by which
neutrophil survival and apoptosis are regulated will help explain
the pathophysiology of AASV and may have implications for the
diagnosis and treatment, also of related diseases.
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